{"id":61724,"date":"2024-03-06T08:17:36","date_gmt":"2024-03-06T08:17:36","guid":{"rendered":"https:\/\/medsname.com\/taficita\/"},"modified":"2026-05-14T05:13:54","modified_gmt":"2026-05-14T05:13:54","slug":"taficita","status":"publish","type":"product","link":"https:\/\/medsbase.com\/cs\/product\/taficita\/","title":{"rendered":"Taficita"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background:#fff8e1;border-left:4px solid #f5a623;padding:18px 22px;margin:0 0 24px 0;border-radius:4px;\">\n<h3 class=\"wp-block-heading\" style=\"margin:0 0 8px 0;font-size:16px;font-weight:700;\">\u26a1 Rychl\u00e1 odpov\u011b\u010f \u2014 Co je Taficita?<\/h3>\n<p style=\"margin:0;\"><strong>Taficita<\/strong> obsahuje <strong>tenofovir alafenamid 25 mg + emtricitabin 200 mg<\/strong> a pou\u017e\u00edv\u00e1 se pro pre-expozi\u010dn\u00ed profylaxi HIV (PrEP) u HIV-negativn\u00edch MSM a transgender \u017een s v\u00fdznamn\u00fdm rizikem. PrEP na b\u00e1zi TAF je schv\u00e1len pro prevenci HIV u <strong>cisgender mu\u017e\u016f, kte\u0159\u00ed maj\u00ed sex s mu\u017ei (MSM) a transgender \u017een<\/strong> (studie DISCOVER, 2019) \u2014 ne pro cisgender \u017eeny, kde jsou d\u016fkazy z klinick\u00fdch studi\u00ed nedostate\u010dn\u00e9. Pouze denn\u00ed d\u00e1vkov\u00e1n\u00ed; nen\u00ed hor\u0161\u00ed ne\u017e TDF\/FTC s v\u00fdrazn\u011b lep\u0161\u00ed bezpe\u010dnost\u00ed pro ledviny a kosti (studie DISCOVER). V\u00fdrobce: Emcure Pharmaceuticals. Pod odborn\u00fdm dohledem; vy\u017eaduje potvrzen\u00ed HIV-negativn\u00edho stavu p\u0159ed zah\u00e1jen\u00edm a ka\u017ed\u00e9 3 m\u011bs\u00edce b\u011bhem terapie.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background:#f6f7fb;border:1px solid #e3e5ee;border-radius:8px;padding:14px 18px;margin:18px 0;font-size:14px;line-height:1.55;\"><strong>Co z\u00edsk\u00e1te s MedsBase:<\/strong> Dod\u00e1v\u00e1no od v\u00fdrobce certifikovan\u00e9ho WHO-GMP \u00b7 Diskr\u00e9tn\u00ed balen\u00ed \u00b7 Celosv\u011btov\u00e1 doprava \u00b7 <a href=\"\/cs\/reviews\/\" rel=\"noopener\">1 400+ ov\u011b\u0159en\u00fdch recenz\u00ed z\u00e1kazn\u00edk\u016f<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size:14px;color:#444;margin:8px 0 18px;\">\ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed <a href=\"https:\/\/medsbase.com\/cs\/medsbase-re-shipment-assurance-policy\/\"><strong>Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n<h3>Pro\u010d objedn\u00e1vat z MedsBase<\/h3>\n<p>Objedn\u00e1v\u00e1n\u00ed z MedsBase v\u00e1m zaji\u0161\u0165uje dod\u00e1vky od v\u00fdrobce certifikovan\u00e9ho WHO-GMP, diskr\u00e9tn\u00ed balen\u00ed v oby\u010dejn\u00e9 ob\u00e1lce, celosv\u011btovou dopravu a hodnocen\u00ed 4,9\u2605 od v\u00edce ne\u017e 1 400 ov\u011b\u0159en\u00fdch z\u00e1kazn\u00edk\u016f. Platby kartou jsou sm\u011brov\u00e1ny p\u0159es regulovan\u00fd krypto-on-ramp \u2014 popis na v\u00fdpisu z va\u0161eho bankovn\u00edho \u00fa\u010dtu bude obsahovat jm\u00e9no procesoru (regulovan\u00e9ho procesoru plateb kartou), nikdy \u201cMedsBase\u201d nebo n\u00e1zev l\u00e9ku. Ka\u017ed\u00e1 z\u00e1silka je pokryta na\u0161\u00edm <a href=\"\/cs\/medsbase-re-shipment-assurance-policy\/\" rel=\"noopener\">Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/a>.<\/p>\n<p><strong>Taficita<\/strong> je <strong>denn\u00ed profylaxe p\u0159ed expozic\u00ed HIV (PrEP)<\/strong> tabletka kombinuj\u00edc\u00ed <strong>tenofovir alafenamid (TAF) 25 mg<\/strong> a <strong>emtricitabin (FTC) 200 mg<\/strong> \u2014 stejn\u00e1 fixn\u00ed kombinace, kter\u00e1 tvo\u0159\u00ed origin\u00e1ln\u00ed p\u0159\u00edpravek Descovy\u00ae vyvinut\u00fd spole\u010dnost\u00ed Gilead Sciences. Taficita je tabletov\u00fd p\u0159\u00edpravek obsahuj\u00edc\u00ed tenofovir alafenamid + emtricitabin od spole\u010dnosti Emcure Pharmaceuticals \u2014 generick\u00fd ekvivalent Descovy ur\u010den\u00fd pro HIV-negativn\u00ed mu\u017ee, kte\u0159\u00ed maj\u00ed sex s mu\u017ei (MSM), a transgender \u017eeny, kte\u0159\u00ed cht\u011bj\u00ed PrEP s lep\u0161\u00edm bezpe\u010dnostn\u00edm profilem pro ledviny a kosti d\u00edky prodrogu TAF oproti star\u0161\u00edm kombinac\u00edm zalo\u017een\u00fdm na TDF.<\/p>\n<p>TAF je <strong>nov\u011bj\u0161\u00ed prodrogov\u00e1 forma tenofoviru<\/strong> vyvinut\u00e1 speci\u00e1ln\u011b k \u0159e\u0161en\u00ed ren\u00e1ln\u00edch a kostn\u00edch ne\u017e\u00e1douc\u00edch \u00fa\u010dink\u016f star\u0161\u00edho tenofovir disoproxil fumar\u00e1tu (TDF). D\u00edky selektivn\u00edmu dod\u00e1v\u00e1n\u00ed tenofoviru do c\u00edlov\u00fdch bun\u011bk dosahuje TAF stejn\u00e9 antivirov\u00e9 aktivity p\u0159i p\u0159ibli\u017en\u011b desetin\u00e1sobn\u011b ni\u017e\u0161\u00ed expozici tenofoviru v plazm\u011b \u2014 co\u017e znamen\u00e1 v\u00fdrazn\u011b ni\u017e\u0161\u00ed toxicitu pro ledviny a kosti p\u0159i dlouhodob\u00e9m denn\u00edm u\u017e\u00edv\u00e1n\u00ed.<\/p>\n<h2 class=\"wp-block-heading\">Co je Taficita?<\/h2>\n<p>Taficita je fixn\u00ed kombinace dvou nukleosidov\u00fdch\/nukleotidov\u00fdch inhibitor\u016f reverzn\u00ed transkript\u00e1zy:<\/p>\n<ul>\n<li><strong>Tenofovir alafenamid (TAF) 25 mg<\/strong> \u2014 prodrog tenofoviru, kter\u00fd se aktivuje p\u0159edev\u0161\u00edm uvnit\u0159 c\u00edlov\u00fdch bun\u011bk (HIV-infikovan\u00fdch nebo n\u00e1chyln\u00fdch k HIV). Poskytuje stejn\u00e9 intracelul\u00e1rn\u00ed hladiny l\u00e9ku jako TDF, p\u0159i\u010dem\u017e hladiny tenofoviru v plazm\u011b jsou p\u0159ibli\u017en\u011b o 90 % ni\u017e\u0161\u00ed<\/li>\n<li><strong>Emtricitabin (FTC) 200 mg<\/strong> \u2014 stejn\u00fd cytidinov\u00fd analog inhibitoru reverzn\u00ed transkript\u00e1zy pou\u017e\u00edvan\u00fd v re\u017eimech TDF\/FTC, s komplement\u00e1rn\u00edm profilem rezistence v\u016f\u010di TAF<\/li>\n<\/ul>\n<p>P\u0159i pou\u017eit\u00ed jako PrEP p\u0159edz\u00e1sob\u00ed Taficita bu\u0148ky n\u00e1chyln\u00e9 k HIV inhibitorem reverzn\u00ed transkript\u00e1zy, tak\u017ee jak\u00fdkoli virus p\u0159enesen\u00fd p\u0159i sexu\u00e1ln\u00edm kontaktu nem\u016f\u017ee dokon\u010dit sv\u016fj krok reverzn\u00ed transkripce, a nem\u016f\u017ee tedy zp\u016fsobit chronickou infekci.<\/p>\n<p><strong>Klinick\u00e1 ekvivalence:<\/strong> Taficita a origin\u00e1ln\u00ed p\u0159\u00edpravek Descovy obsahuj\u00ed identick\u00e9 \u00fa\u010dinn\u00e9 l\u00e1tky (TAF 25 mg + FTC 200 mg) a jsou vyr\u00e1b\u011bny podle standard\u016f bioekvivalence stanoven\u00fdch l\u00e9kov\u00fdmi regula\u010dn\u00edmi org\u00e1ny. Klinick\u00e9 d\u016fkazy ze studie DISCOVER (klinick\u00e1 studie PrEP s TAF\/FTC) plat\u00ed stejn\u011b pro v\u0161echny v\u00fdrobce t\u00e9to fixn\u00ed kombinace.<\/p>\n<h2 class=\"wp-block-heading\">TAF vs TDF \u2014 Pro\u010d bych si m\u011bl vybrat tento p\u0159\u00edpravek?<\/h2>\n<table>\n<thead>\n<tr>\n<th>Zv\u00e1\u017een\u00ed<\/th>\n<th>TAF\/FTC (tento p\u0159\u00edpravek)<\/th>\n<th>TDF\/FTC (\",\" apod.)<a href=\"\/cs\/tenvir-em\/\" rel=\"noopener\">Tenvir EM<\/a>, Ren\u00e1ln\u00ed bezpe\u010dnost<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong>V\u00fdrazn\u011b lep\u0161\u00ed \u2014 ~90% ni\u017e\u0161\u00ed expozice tenofoviru v plazm\u011b. Preferov\u00e1no pro eGFR 30\u201359 ml\/min (kde je TDF kontraindikov\u00e1n)<\/strong><\/td>\n<td>M\u00edrn\u00fd pokles eGFR p\u0159i dlouhodob\u00e9m u\u017e\u00edv\u00e1n\u00ed; kontraindikov\u00e1no pod eGFR 60 ml\/min<\/td>\n<td>M\u00edrn\u00fd pokles eGFR p\u0159i dlouhodob\u00e9m u\u017e\u00edv\u00e1n\u00ed; kontraindikov\u00e1no p\u0159i eGFR pod 60 mL\/min<\/td>\n<\/tr>\n<tr>\n<td><strong>Klinicky v\u00fdznamn\u00e1 v\u00fdhoda \u2014 nebyl pozorov\u00e1n v\u00fdznamn\u00fd pokles BMD ve studii DISCOVER. Preferov\u00e1no pro osteopenii\/osteopor\u00f3zu<\/strong><\/td>\n<td>Klinicky v\u00fdznamn\u00e1 v\u00fdhoda \u2014 ve studii DISCOVER nebyl pozorov\u00e1n v\u00fdznamn\u00fd pokles BMD. Preferov\u00e1no pro osteopenii\/osteopor\u00f3zu.<\/td>\n<td>Mal\u00fd, ale skute\u010dn\u00fd pokles BMD, zejm\u00e9na v prvn\u00edch 2 letech.<\/td>\n<\/tr>\n<tr>\n<td><strong>Pouze cisgender MSM a transgender \u017eeny<\/strong><\/td>\n<td><strong>Pouze cisgender MSM a transgenderov\u00e9 \u017eeny<\/strong> V\u0161echny rizikov\u00e9 populace \u2014 cis-mu\u017ei, cis-\u017eeny, trans lid\u00e9, u\u017eivatel\u00e9 injek\u010dn\u00edch drog (iPrEx, PROUD, Partners PrEP, HPTN 084)<\/td>\n<td>V\u0161echny rizikov\u00e9 populace \u2014 cis-mu\u017ei, cis-\u017eeny, transgender osoby, injek\u010dn\u00ed u\u017eivatel\u00e9 drog (iPrEx, PROUD, Partners PrEP, HPTN 084)<\/td>\n<\/tr>\n<tr>\n<td><strong>Pouze denn\u011b. N\u00e1razov\u00e9 u\u017e\u00edv\u00e1n\u00ed 2-1-1 nen\u00ed<\/strong><\/td>\n<td>validov\u00e1no <strong>not validated<\/strong> pro TAF<\/td>\n<td>Denn\u011b nebo na vy\u017e\u00e1d\u00e1n\u00ed 2-1-1 pro cis-MSM (protokol IPERGAY)<\/td>\n<\/tr>\n<tr>\n<td><strong>Cena<\/strong><\/td>\n<td>obvykle vy\u0161\u0161\u00ed ne\u017e generika TDF\/FTC<\/td>\n<td>nejlevn\u011bj\u0161\u00ed mo\u017enost PrEP<\/td>\n<\/tr>\n<tr>\n<td><strong>Zm\u011bny hmotnosti<\/strong><\/td>\n<td>mal\u00e9 zv\u00fd\u0161en\u00ed hmotnosti pozorov\u00e1no (~1\u20132 kg za rok)<\/td>\n<td>ztr\u00e1ta hmotnosti pozorov\u00e1na (~1\u20132 kg za rok)<\/td>\n<\/tr>\n<tr>\n<td><strong>Lipidov\u00fd profil<\/strong><\/td>\n<td>m\u00edrn\u00e9 zv\u00fd\u0161en\u00ed LDL a celkov\u00e9ho cholesterolu<\/td>\n<td>m\u00edrn\u00e9 sn\u00ed\u017een\u00ed LDL (prost\u0159ednictv\u00edm TDF)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>pravidlo palce:<\/strong> pokud m\u00e1te norm\u00e1ln\u00ed funkci ledvin, \u017e\u00e1dn\u00e9 obavy o hustotu kost\u00ed a chcete nej\u0161ir\u0161\u00ed schv\u00e1lenou indikaci (a nejni\u017e\u0161\u00ed n\u00e1klady), TDF\/FTC (<a href=\"\/cs\/tenvir-em\/\" rel=\"noopener\">Tenvir EM<\/a>) je l\u00e9kem prvn\u00ed volby. Pokud m\u00e1te sn\u00ed\u017eenou eGFR (30\u201359), osteopenii\/osteopor\u00f3zu, nebo jste cis-mu\u017e maj\u00edc\u00ed sex s mu\u017ei (MSM) \u010di transgender \u017eena preferuj\u00edc\u00ed bezpe\u010dn\u011bj\u0161\u00ed dlouhodob\u00fd profil, Taficita je vhodn\u011bj\u0161\u00ed volbou.<\/p>\n<h2 class=\"wp-block-heading\">Jak Taficita funguje jako PrEP<\/h2>\n<p>Po po\u017eit\u00ed z\u016fst\u00e1v\u00e1 TAF stabiln\u00ed v plazm\u011b (na rozd\u00edl od TDF, kter\u00fd se v krvi \u0161t\u011bp\u00ed na tenofovir) a je selektivn\u011b vychyt\u00e1v\u00e1n lymfocyty, st\u0159evn\u00ed sliznic\u00ed a dal\u0161\u00edmi bu\u0148kami c\u00edlen\u00fdmi HIV. Uvnit\u0159 t\u011bchto bun\u011bk je TAF p\u0159em\u011bn\u011bn bun\u011b\u010dn\u00fdmi enzymy na aktivn\u00ed metabolit tenofovir difosf\u00e1t, kter\u00fd sout\u011b\u017e\u00ed s p\u0159irozen\u00fdmi nukleotidy u HIV reverzn\u00ed transkript\u00e1zy a ukon\u010duje elongaci DNA \u0159et\u011bzce.<\/p>\n<p>Kl\u00ed\u010dov\u00e9 farmakokinetick\u00e9 body ovliv\u0148uj\u00edc\u00ed ochranu:<\/p>\n<ul>\n<li><strong>Koncentrace v rekt\u00e1ln\u00ed tk\u00e1ni<\/strong> rychle dosahuje ochrann\u00fdch hladin p\u0159i denn\u00edm d\u00e1vkov\u00e1n\u00ed \u2014 data studie DISCOVER prok\u00e1zala robustn\u00ed ochranu u MSM u\u017e\u00edvaj\u00edc\u00edch \u22654 d\u00e1vky t\u00fddn\u011b<\/li>\n<li><strong>Expozice cervikovagin\u00e1ln\u00ed a injek\u010dn\u00ed<\/strong> \u2014 TAF\/FTC je <strong>NEN\u00cd schv\u00e1len FDA<\/strong> pro cisgender \u017eeny. Studie DISCOVER nezahrnovala cis-\u017eeny, tak\u017ee \u00fa\u010dinnost p\u0159i vagin\u00e1ln\u00edm sexu a expozici injek\u010dn\u00edmi drogami nebyla form\u00e1ln\u011b prok\u00e1z\u00e1na. Cis-\u017eeny hledaj\u00edc\u00ed PrEP by m\u011bly pou\u017e\u00edvat TDF\/FTC (kter\u00e9 m\u00e1 siln\u00e1 data ze studi\u00ed Partners PrEP a HPTN 084)<\/li>\n<li><strong>Polo\u010das tenofovir difosf\u00e1tu (intracelul\u00e1rn\u00ed)<\/strong> je dostate\u010dn\u011b dlouh\u00fd na to, aby toleroval ob\u010dasn\u00e9 vynech\u00e1n\u00ed d\u00e1vky, ale vynech\u00e1n\u00ed v\u00edce d\u00e1vek t\u00fddn\u011b v\u00fdznamn\u011b sni\u017euje ochranu<\/li>\n<li><strong>Kryt\u00ed ocasu<\/strong> po posledn\u00ed expozici: pokra\u010dujte v d\u00e1vkov\u00e1n\u00ed alespo\u0148 28 dn\u00ed po posledn\u00ed potenci\u00e1ln\u00ed expozici HIV, aby bylo pokryto inkuba\u010dn\u00ed okno<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">P\u0159ed zah\u00e1jen\u00edm PrEP \u2013 povinn\u00e9 testy<\/h2>\n<p>Po\u017eadavky na testov\u00e1n\u00ed p\u0159ed zah\u00e1jen\u00edm PrEP s TAF\/FTC jsou stejn\u00e9 jako u TDF\/FTC:<\/p>\n<table>\n<thead>\n<tr>\n<th>Test<\/th>\n<th>Pro\u010d je to d\u016fle\u017eit\u00e9<\/th>\n<th>Na\u010dasov\u00e1n\u00ed<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong>HIV test (4. generace antigen\/protil\u00e1tka nebo HIV RNA)<\/strong><\/td>\n<td>Mus\u00ed b\u00fdt potvrzen negativn\u00ed v\u00fdsledek. Zah\u00e1jen\u00ed PrEP p\u0159i nev\u011bdom\u00e9 HIV-pozitivit\u011b vede k rezistenci (M184V, K65R), kter\u00e1 ohro\u017euje budouc\u00ed mo\u017enosti l\u00e9\u010dby HIV<\/td>\n<td>Do 7 dn\u016f od zah\u00e1jen\u00ed<\/td>\n<\/tr>\n<tr>\n<td><strong>Povrchov\u00fd protil\u00e1tkov\u00fd test proti hepatitid\u011b B (anti-HBs)<\/strong><\/td>\n<td>TAF\/FTC tak\u00e9 l\u00e9\u010d\u00ed HBV. U pacient\u016f s HBV m\u016f\u017ee vysazen\u00ed PrEP zp\u016fsobit z\u00e1va\u017en\u00e9 vzplanut\u00ed hepatitidy \u2014 \u0159e\u0161te ve spolupr\u00e1ci s hepatology<\/td>\n<td>V\u00fdchoz\u00ed hodnota<\/td>\n<\/tr>\n<tr>\n<td><strong>Ren\u00e1ln\u00ed funkce (kreatinin, eGFR)<\/strong><\/td>\n<td>TAF je \u0161etrn\u011bj\u0161\u00ed k ledvin\u00e1m ne\u017e TDF, ale st\u00e1le vy\u017eaduje eGFR \u226530 ml\/min. Pod touto hodnotou jsou bezpe\u010dnostn\u00ed data omezen\u00e1<\/td>\n<td>V\u00fdchoz\u00ed hodnota, pot\u00e9 ka\u017ed\u00fdch 12 m\u011bs\u00edc\u016f (m\u00e9n\u011b \u010dasto ne\u017e u TDF)<\/td>\n<\/tr>\n<tr>\n<td><strong>Test na pohlavn\u011b p\u0159enosn\u00e9 infekce (syfilis, chlamydie, kapavka)<\/strong><\/td>\n<td>PrEP zabra\u0148uje infekci HIV, nikoli jin\u00fdm pohlavn\u011b p\u0159enosn\u00fdm infekc\u00edm. V\u00fdchoz\u00ed vy\u0161et\u0159en\u00ed a \u010dtvrtletn\u00ed screening jsou standardem p\u00e9\u010de<\/td>\n<td>V\u00fdchoz\u00ed hodnota, ka\u017ed\u00e9 3 m\u011bs\u00edce<\/td>\n<\/tr>\n<tr>\n<td><strong>Lipidov\u00fd panel (v\u00fdchoz\u00ed hodnota pro srovn\u00e1n\u00ed)<\/strong><\/td>\n<td>TAF\/FTC m\u00edrn\u011b zvy\u0161uje LDL a celkov\u00fd cholesterol. Doporu\u010duje se v\u00fdchoz\u00ed m\u011b\u0159en\u00ed, aby bylo mo\u017en\u00e9 interpretovat p\u0159\u00edpadn\u00e9 zm\u011bny<\/td>\n<td>V\u00fdchoz\u00ed hodnota, pot\u00e9 podle klinick\u00e9 pot\u0159eby<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>Pr\u016fb\u011b\u017en\u00e9 monitorov\u00e1n\u00ed:<\/strong> Test na HIV ka\u017ed\u00e9 3 m\u011bs\u00edce. Screening pohlavn\u011b p\u0159enosn\u00fdch infekc\u00ed ka\u017ed\u00e9 3 m\u011bs\u00edce. Funkce ledvin alespo\u0148 jednou ro\u010dn\u011b. Lipidov\u00fd panel podle klinick\u00e9 pot\u0159eby. Stav HBV nen\u00ed nutn\u00e9 znovu testovat, pokud byl na po\u010d\u00e1tku negativn\u00ed, pokud se neobjev\u00ed nov\u00e9 rizikov\u00e9 faktory.<\/p>\n<h2 class=\"wp-block-heading\">D\u00e1vkov\u00e1n\u00ed<\/h2>\n<p><strong>Pouze denn\u011b.<\/strong> Jedna tableta u\u017e\u00edvan\u00e1 ka\u017ed\u00fd den ve stejnou dobu. Na rozd\u00edl od TDF\/FTC, <strong>on-demand protokol 2-1-1 (IPERGAY) NEN\u00cd ov\u011b\u0159en pro TAF\/FTC<\/strong> \u2014 odli\u0161n\u00e1 bun\u011b\u010dn\u00e1 farmakokinetika TAF nebyla studov\u00e1na v on-demand d\u00e1vkovac\u00edch studi\u00edch a neexistuje d\u016fkazov\u00e1 z\u00e1kladna pro jeho podporu. Pokud chcete flexibilitu on-demand d\u00e1vkov\u00e1n\u00ed, pou\u017eijte TDF\/FTC (<a href=\"\/cs\/tenvir-em\/\" rel=\"noopener\">Tenvir EM<\/a>) m\u00edsto toho.<\/p>\n<p><strong>Pokud vynech\u00e1te d\u00e1vku:<\/strong> vezm\u011bte ji co nejd\u0159\u00edve, pokud si vzpomenete do 24 hodin. Pokud uplynulo v\u00edce ne\u017e 24 hodin, vynechanou d\u00e1vku vynechejte a pokra\u010dujte v pl\u00e1novan\u00e9m d\u00e1vkov\u00e1n\u00ed \u2014 ned\u00e1vejte dvojn\u00e1sobnou d\u00e1vku.<\/p>\n<p><strong>Na\u010dasov\u00e1n\u00ed s j\u00eddlem:<\/strong> lze u\u017e\u00edvat s j\u00eddlem nebo nala\u010dno. Pokud je v prvn\u00edch t\u00fddnech probl\u00e9m s nevolnost\u00ed, pom\u00e1h\u00e1 u\u017e\u00edv\u00e1n\u00ed s j\u00eddlem.<\/p>\n<h2 class=\"wp-block-heading\">Vedlej\u0161\u00ed \u00fa\u010dinky<\/h2>\n<p>TAF\/FTC je obecn\u011b l\u00e9pe sn\u00e1\u0161en ne\u017e TDF\/FTC, zejm\u00e9na v prvn\u00edch t\u00fddnech. V\u011bt\u0161ina vedlej\u0161\u00edch \u00fa\u010dink\u016f se objevuje v \u201cpo\u010d\u00e1te\u010dn\u00edch\u201d 2\u20134 t\u00fddnech a s pokra\u010duj\u00edc\u00edm u\u017e\u00edv\u00e1n\u00edm vymiz\u00ed.<\/p>\n<table>\n<thead>\n<tr>\n<th>Z\u00e1va\u017enost<\/th>\n<th>Vedlej\u0161\u00ed \u00fa\u010dinek<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong>B\u011b\u017en\u00e9, p\u0159echodn\u00e9<\/strong><\/td>\n<td>M\u00edrn\u00e1 nevolnost, pr\u016fjem, b\u0159i\u0161n\u00ed diskomfort, bolest hlavy. Obecn\u011b m\u00edrn\u011bj\u0161\u00ed ne\u017e u TDF<\/td>\n<\/tr>\n<tr>\n<td><strong>M\u00e9n\u011b \u010dast\u00e9<\/strong><\/td>\n<td>P\u0159ib\u00fdv\u00e1n\u00ed na v\u00e1ze (p\u0159ibli\u017en\u011b 1\u20132 kg za 1 rok), m\u00edrn\u011b zv\u00fd\u0161en\u00fd LDL a celkov\u00fd cholesterol, z\u00e1vrat\u011b, nespavost, vyr\u00e1\u017eka<\/td>\n<\/tr>\n<tr>\n<td><strong>Vz\u00e1cn\u00e9, ale z\u00e1va\u017en\u00e9<\/strong><\/td>\n<td>Lakt\u00e1tov\u00e1 acid\u00f3za, v\u00fdrazn\u00e9 zv\u00fd\u0161en\u00ed jatern\u00edch enzym\u016f, jatern\u00ed steat\u00f3za, z\u00e1va\u017en\u00e1 alergick\u00e1 reakce. P\u0159i siln\u00e9 \u00fanav\u011b, nevysv\u011btliteln\u00e9 bolesti sval\u016f, p\u0159etrv\u00e1vaj\u00edc\u00ed nevolnosti nebo \u017eloutence vyhledejte neodkladnou l\u00e9ka\u0159skou pomoc<\/td>\n<\/tr>\n<tr>\n<td><strong>Specifick\u00e9 pro HBV<\/strong><\/td>\n<td>N\u00e1hl\u00e9 vysazen\u00ed TAF\/FTC u pacient\u016f s HBV m\u016f\u017ee vyvolat akutn\u00ed vzplanut\u00ed hepatitidy \u2013 potenci\u00e1ln\u011b \u017eivot ohro\u017euj\u00edc\u00ed. Pacienti s HBV na PrEP <strong>nesm\u011bj\u00ed n\u00e1hle p\u0159estat<\/strong> bez konzultace s hepatologem<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>Ve srovn\u00e1n\u00ed s TDF\/FTC:<\/strong> ni\u017e\u0161\u00ed ren\u00e1ln\u00ed toxicita, men\u0161\u00ed pokles kostn\u00ed miner\u00e1ln\u00ed denzity, m\u00edrn\u011b vy\u0161\u0161\u00ed \u00fa\u010dinky na v\u00e1hu a lipidy, podobn\u00e1 gastrointestin\u00e1ln\u00ed sn\u00e1\u0161enlivost, stejn\u00e9 zv\u00e1\u017een\u00ed HBV.<\/p>\n<h2 class=\"wp-block-heading\">Kontraindikace a preventivn\u00ed opat\u0159en\u00ed<\/h2>\n<ul>\n<li><strong>Prok\u00e1zan\u00fd HIV pozitivn\u00ed status<\/strong> \u2014 TAF\/FTC je dvoul\u00e9\u010debn\u00fd re\u017eim, kter\u00fd je sub-terapeutick\u00fd pro l\u00e9\u010dbu HIV; jeho pou\u017eit\u00ed vede k selekci rezistentn\u00edch mutac\u00ed, kter\u00e9 ohro\u017euj\u00ed budouc\u00ed l\u00e9\u010debn\u00e9 mo\u017enosti<\/li>\n<li><strong>eGFR pod 30 ml\/min<\/strong> \u2014 \u00fadaje o bezpe\u010dnosti a \u00fa\u010dinnosti jsou omezen\u00e9; doporu\u010duje se konzultace s odborn\u00edkem<\/li>\n<li><strong>Akutn\u00ed hepatitida<\/strong> \u2014 bu\u010fte opatrn\u00ed a konzultujte hepatologa<\/li>\n<li><strong>Kojen\u00ed<\/strong> \u2014 tenofovir se vylu\u010duje do mate\u0159sk\u00e9ho ml\u00e9ka. Vylu\u010dov\u00e1n\u00ed TAF je ni\u017e\u0161\u00ed ne\u017e u TDF, ale doporu\u010duje se posouzen\u00ed rizika a p\u0159\u00ednos\u016f s l\u00e9ka\u0159em<\/li>\n<li><strong>\u017deny vyhled\u00e1vaj\u00edc\u00ed PrEP pro expozici p\u0159i vagin\u00e1ln\u00edm\/\u010deln\u00edm styku<\/strong> \u2014 pou\u017eijte rad\u011bji TDF\/FTC; TAF\/FTC nem\u00e1 pro tuto populaci schv\u00e1len\u00ed regul\u00e1tor\u016f ani data z klinick\u00fdch studi\u00ed<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Interakce s l\u00e9\u010divy<\/h2>\n<ul>\n<li><strong>Rifampin, rifabutin, karbamazepin, fenytoin, t\u0159ezalka te\u010dkovan\u00e1<\/strong> \u2014 siln\u00e9 induktory enzym\u016f, kter\u00e9 aktivuj\u00ed TAF. <strong>Kontraindikov\u00e1no<\/strong> nebo vy\u017eaduje \u00fapravu d\u00e1vkov\u00e1n\u00ed; konzultujte s l\u00e9ka\u0159em<\/li>\n<li><strong>Nefrotoxick\u00e9 l\u00e9ky<\/strong> (aminoglykosidy, amfotericin B, cidofovir, intraven\u00f3zn\u00ed pentamidin) \u2014 st\u00e1le je vhodn\u00e9 se jim vyhnout navzdory lep\u0161\u00edmu ren\u00e1ln\u00edmu profilu TAF<\/li>\n<li><strong>Didanosin (ddI)<\/strong> \u2014 vyvarujte se kombinov\u00e1n\u00ed (historick\u00e9 obavy z ko-toxicity z obdob\u00ed TDF, pro TAF omezen\u00e1 data, ale opatrnost je na m\u00edst\u011b)<\/li>\n<li><strong>HIV postexpozi\u010dn\u00ed profylaxe (PEP) re\u017eimy<\/strong> \u2014 pokud je po vysoce rizikov\u00e9 expozici nutn\u00e1 PEP, \u0159e\u0161te ve spolupr\u00e1ci s odborn\u00edkem na HIV<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Jak u\u017e\u00edvat Taficitu \u2014 praktick\u00e9 pokyny<\/h2>\n<ul>\n<li>Tabletu spolkn\u011bte celou s vodou, <strong>ve stejnou dobu ka\u017ed\u00fd den<\/strong>. Vynech\u00e1n\u00ed v\u00edce ne\u017e 1\u20132 d\u00e1vek t\u00fddn\u011b v\u00fdrazn\u011b sni\u017euje ochranu<\/li>\n<li>Lze u\u017e\u00edvat s j\u00eddlem i bez j\u00eddla<\/li>\n<li>Pokud je d\u00e1vka vynech\u00e1na a vzpomenete si na ni do 24 hodin, u\u017eijte ji co nejd\u0159\u00edve; jinak vynechanou d\u00e1vku vynechejte<\/li>\n<li>Nep\u0159est\u00e1vejte <strong>ne<\/strong> nep\u0159est\u00e1vejte s PrEP n\u00e1hle, pokud jste HBV-pozitivn\u00ed, bez konzultace s l\u00e9ka\u0159em<\/li>\n<li>Pokra\u010dujte alespo\u0148 28 dn\u00ed po posledn\u00ed sexu\u00e1ln\u00ed expozici (2-d\u00e1vkov\u00fd ocas), aby bylo pokryto inkuba\u010dn\u00ed obdob\u00ed<\/li>\n<li>Vracejte se \u010dtvrtletn\u011b na testov\u00e1n\u00ed HIV a pohlavn\u011b p\u0159enosn\u00fdch chorob; ro\u010dn\u011b na vy\u0161et\u0159en\u00ed ledvin a lipidov\u00e9ho panelu<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Skladov\u00e1n\u00ed<\/h2>\n<ul>\n<li>Skladujte p\u0159i teplot\u011b do 30\u00b0C na such\u00e9m a chladn\u00e9m m\u00edst\u011b<\/li>\n<li>Uchov\u00e1vejte v p\u016fvodn\u00ed lahvi\u010dce nebo blistrov\u00e9m balen\u00ed a\u017e do pou\u017eit\u00ed<\/li>\n<li>Nepou\u017e\u00edvejte po datu expirace uveden\u00e9m na obalu<\/li>\n<li>Uchov\u00e1vejte mimo dosah d\u011bt\u00ed a dom\u00e1c\u00edch zv\u00ed\u0159at<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Souvisej\u00edc\u00ed mo\u017enosti PrEP na MedsBase<\/h2>\n<ul>\n<li><a href=\"\/cs\/tenvir-em\/\" rel=\"noopener\"><strong>Tenvir EM<\/strong><\/a> \u2014 TDF\/FTC od spole\u010dnosti Cipla (generick\u00fd Truvada). Na\u0161e nej\u010dast\u011bji doporu\u010dovan\u00e1 str\u00e1nka o PrEP. Schv\u00e1leno pro v\u0161echny rizikov\u00e9 skupiny v\u010detn\u011b cis-\u017een<\/li>\n<li><a href=\"\/cs\/ricovir-em\/\" rel=\"noopener\"><strong>Ricovir EM<\/strong><\/a> \u2014 Alternativa TDF\/FTC od Mylan\/Viatris<\/li>\n<li><a href=\"\/cs\/tavin-em\/\" rel=\"noopener\"><strong>Tavin EM<\/strong><\/a> \u2014 Alternativa TDF\/FTC od Emcure<\/li>\n<li><a href=\"\/cs\/tenof-em\/\" rel=\"noopener\"><strong>Tenof EM<\/strong><\/a> \u2014 Alternativa TDF\/FTC od Hetero<\/li>\n<li><a href=\"\/cs\/std-protection-pack\/\" rel=\"noopener\"><strong>Bal\u00ed\u010dek ochrany proti STD<\/strong><\/a> \u2014 Kombinace TDF\/FTC + doxycyklin (DoxyPEP) + azithromycin pro \u0161ir\u0161\u00ed pokryt\u00ed sexu\u00e1ln\u00edho zdrav\u00ed<\/li>\n<\/ul>\n<p>Viz tak\u00e9 <a href=\"\/cs\/hiv-medication\/\">L\u00e9ky na HIV<\/a> a <a href=\"\/cs\/sexual-health\/\">Sexu\u00e1ln\u00ed zdrav\u00ed<\/a> kategorie.<\/p>\n<h2 id=\"faqs\">\u010casto kladen\u00e9 dotazy<\/h2>\n<h3 class=\"wp-block-heading\">Je Taficita stejn\u00e1 jako Descovy?<\/h3>\n<p>Klinicky ekvivalentn\u00ed. Taficita obsahuje p\u0159esn\u011b stejn\u00e9 \u00fa\u010dinn\u00e9 l\u00e1tky jako Descovy\u00ae (tenofovir alafenamid 25 mg + emtricitabin 200 mg) a je vyr\u00e1b\u011bna podle standard\u016f farmaceutick\u00e9 bioekvivalence. Klinick\u00e9 d\u016fkazy z studie DISCOVER, kter\u00e9 podporuj\u00ed pou\u017eit\u00ed TAF\/FTC jako PrEP, plat\u00ed pro v\u0161echny bioekvivalentn\u00ed generick\u00e9 verze t\u00e9to fixn\u00ed kombinace.<\/p>\n<h3 class=\"wp-block-heading\">Mohu pou\u017e\u00edvat Taficitu, pokud jsem cisgender \u017eena?<\/h3>\n<p><strong>Ne jako prvn\u00ed volbu.<\/strong> TAF\/FTC je schv\u00e1len pro PrEP pouze u cisgender MSM a transgender \u017een, proto\u017ee studie DISCOVER nezahrnovala cisgender \u017eeny. Pokud jste cisgender \u017eena hledaj\u00edc\u00ed PrEP, TDF\/FTC (nap\u0159\u00edklad <a href=\"\/cs\/tenvir-em\/\" rel=\"noopener\">Tenvir EM<\/a>) m\u00e1 siln\u00e9 d\u016fkazy ze studi\u00ed Partners PrEP a HPTN 084 a je spr\u00e1vnou prvn\u00ed volbou.<\/p>\n<h3 class=\"wp-block-heading\">Jak \u00fa\u010dinn\u00fd je Taficita ve srovn\u00e1n\u00ed s TDF\/FTC?<\/h3>\n<p>Studie DISCOVER (2019) prok\u00e1zala, \u017ee TAF\/FTC je <strong>nem\u00e9n\u011b \u00fa\u010dinn\u00fd<\/strong> ne\u017e TDF\/FTC v prevenci HIV u MSM a transgender \u017een, s <strong>lep\u0161\u00edm ren\u00e1ln\u00edm a kostn\u00edm profilem bezpe\u010dnosti<\/strong>. Oba re\u017eimy sni\u017euj\u00ed riziko HIV o &gt;99 % p\u0159i vysok\u00e9 adherenci.<\/p>\n<h3 class=\"wp-block-heading\">Pro\u010d bych m\u011bl platit v\u00edce za Taficitu oproti generick\u00e9 verzi TDF?<\/h3>\n<p>Dva hlavn\u00ed d\u016fvody: (1) v\u00fdrazn\u011b men\u0161\u00ed dopad na funkci ledvin a hustotu kost\u00ed, co\u017e je d\u016fle\u017eit\u00e9, pokud pl\u00e1nujete u\u017e\u00edvat PrEP dlouhodob\u011b nebo m\u00e1te st\u00e1vaj\u00edc\u00ed rizikov\u00e9 faktory; (2) m\u00e1te z\u00e1kladn\u00ed ren\u00e1ln\u00ed poruchu (eGFR 30\u201359 ml\/min), kde je TDF kontraindikov\u00e1n. Pro jinak zdrav\u00e9 u\u017eivatele bez t\u011bchto faktor\u016f je TDF\/FTC stejn\u011b \u00fa\u010dinn\u00fd a levn\u011bj\u0161\u00ed.<\/p>\n<h3 class=\"wp-block-heading\">Mohu u\u017e\u00edvat Taficitu podle pot\u0159eby (\u201con-demand\u201d)?<\/h3>\n<p><strong>Ne.<\/strong> Protokol 2-1-1 (on-demand) je <strong>not validated<\/strong> pro TAF. Denn\u00ed d\u00e1vkov\u00e1n\u00ed je jedin\u00e9 podlo\u017een\u00e9 d\u016fkazy. Pokud chcete d\u00e1vkov\u00e1n\u00ed na vy\u017e\u00e1d\u00e1n\u00ed a jste cisgender MSM, pou\u017eijte rad\u011bji TDF\/FTC \u2014 data z IPERGAY a Prevenir podporuj\u00ed re\u017eim 2-1-1 pro TDF\/FTC.<\/p>\n<h3 class=\"wp-block-heading\">A co p\u0159ib\u00edr\u00e1n\u00ed na v\u00e1ze?<\/h3>\n<p>TAF\/FTC je ve studi\u00edch spojov\u00e1n s m\u00edrn\u00fdm n\u00e1r\u016fstem hmotnosti (~1\u20132 kg za rok). Mechanismus nen\u00ed pln\u011b objasn\u011bn. U v\u011bt\u0161iny u\u017eivatel\u016f je to klinicky nev\u00fdznamn\u00e9, ale jde o re\u00e1ln\u00fd rozd\u00edl oproti TDF\/FTC, kter\u00fd b\u00fdv\u00e1 v\u00e1hov\u011b neutr\u00e1ln\u00ed.<\/p>\n<h3 class=\"wp-block-heading\">Pot\u0159ebuji st\u00e1le kondomy?<\/h3>\n<p><strong>Ano.<\/strong> PrEP chr\u00e1n\u00ed pouze p\u0159ed HIV. Kondomy sni\u017euj\u00ed riziko dal\u0161\u00edch STI (chlamydie, kapavka, syfilis, herpes, HPV, opi\u010d\u00ed ne\u0161tovice) a ot\u011bhotn\u011bn\u00ed. PrEP + kondomy + \u010dtvrtletn\u00ed testov\u00e1n\u00ed na STI + o\u010dkov\u00e1n\u00ed (HPV, HepA, HepB, pokud nejste imunn\u00ed) spole\u010dn\u011b tvo\u0159\u00ed komplexn\u00ed strategii sexu\u00e1ln\u00edho zdrav\u00ed.<\/p>\n<h3 class=\"wp-block-heading\">Co se stane, kdy\u017e p\u0159estanu u\u017e\u00edvat Taficitu?<\/h3>\n<p>Pokud jste HIV-negativn\u00ed a HBV-negativn\u00ed, m\u016f\u017eete bezpe\u010dn\u011b p\u0159estat po 28denn\u00edm \u201eocasu\u201c po posledn\u00ed expozici HIV. Pokud jste HBV-pozitivn\u00ed, <strong>nep\u0159est\u00e1vejte bez \u00fa\u010dasti l\u00e9ka\u0159e<\/strong> \u2014 n\u00e1hl\u00e9 vysazen\u00ed TAF u chronick\u00e9 HBV m\u016f\u017ee vyvolat akutn\u00ed vzplanut\u00ed hepatitidy.<\/p>\n<h3 class=\"wp-block-heading\">Mohu p\u0159ej\u00edt z TDF\/FTC na Taficitu?<\/h3>\n<p>Ano, a to je b\u011b\u017en\u00e9 klinick\u00e9 rozhodnut\u00ed p\u0159i zhor\u0161en\u00ed funkce ledvin, obav\u00e1ch o hustotu kost\u00ed nebo p\u0159i priorit\u011b dlouhodob\u00e9 bezpe\u010dnosti. P\u0159echod by m\u011bl b\u00fdt \u0159\u00edzen l\u00e9ka\u0159em s odpov\u00eddaj\u00edc\u00edm n\u00e1sledn\u00fdm testov\u00e1n\u00edm.<\/p>\n<h3 class=\"wp-block-heading\">Je Taficita dostupn\u00e1 bez p\u0159edpisu?<\/h3>\n<p><strong>Ne.<\/strong> PrEP je re\u017eim vy\u017eaduj\u00edc\u00ed odborn\u00fd dohled, kter\u00fd potvrzuje v\u00fdchoz\u00ed HIV-negativn\u00ed stav, testy funkce ledvin a HBV a n\u00e1sledn\u00e9 kontroly ka\u017ed\u00e9 3 m\u011bs\u00edce. Neza\u010d\u00ednejte s PrEP bez l\u00e9ka\u0159sk\u00e9ho potvrzen\u00ed HIV-negativn\u00edho stavu a z\u00e1kladn\u00edch bezpe\u010dnostn\u00edch test\u016f.<\/p>\n<p><!-- medsbase-faq-h3-converted --><\/p>\n<p class=\"medsbase-bundle-link-2026-05-01\" data-marker=\"mb-bundle-link-prep-starter-pack\">Taficita (TAF\/FTC) pokr\u00fdv\u00e1 pouze PrEP proti HIV; pro vrstven\u00fd re\u017eim PrEP + bakteri\u00e1ln\u00ed STI viz na\u0161i <a href='\/cs\/prep-starter-pack\/'>PrEP Starter Pack (Tenvir-EM + doxycyklin 100 mg)<\/a> \u2014 zaveden\u00e1 kombinace PrEP TDF\/FTC s pokryt\u00edm doxy-PEP za ni\u017e\u0161\u00ed kombinovanou cenu.<\/p>\n<p class=\"medsbase-link-boost-2026-05-08\" data-marker=\"mb-link-boost-tenvir-em\">Jedinci za\u010d\u00ednaj\u00edc\u00ed s PrEP, kte\u0159\u00ed nemaj\u00ed p\u0159\u00edstup k TAF-based <a href=\"https:\/\/medsbase.com\/cs\/taficita\/\">Taficita<\/a> m\u016f\u017ee zv\u00e1\u017eit <a href=\"https:\/\/medsbase.com\/cs\/tenvir-em\/\">Tenvir EM (tenofovir disoproxil fumar\u00e1t 300 mg + emtricitabin 200 mg)<\/a> jako klinicky ekvivalentn\u00ed alternativu TDF\/FTC, se stejn\u00fdm denn\u00edm d\u00e1vkov\u00e1n\u00edm a ekvivalentn\u00edmi dlouhodob\u00fdmi \u00fadaji o \u00fa\u010dinnosti PrEP.<\/p>\n<p class=\"medsbase-link-boost-2026-05-10\" data-marker=\"mb-link-boost-avonza\">P\u0159edepisuj\u00edc\u00ed l\u00e9ka\u0159i p\u0159i posuzov\u00e1n\u00ed star\u0161\u00edch mo\u017enost\u00ed zalo\u017een\u00fdch na TDF vedle <a href=\"https:\/\/medsbase.com\/cs\/taficita\/\">Taficita (tenofovir alafenamid 25 mg + emtricitabin 200 mg)<\/a> \u010dasto uv\u00e1d\u011bj\u00ed <a href=\"https:\/\/medsbase.com\/cs\/avonza\/\">Avonza (TDF \/ lamivudin \/ efavirenz)<\/a> jako zaveden\u00fd benchmark p\u0159edchoz\u00ed linie p\u0159i hodnocen\u00ed n\u00e1kladov\u00e9 dostupnosti v prost\u0159ed\u00ed s omezen\u00fdmi zdroji.<\/p>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h2 id=\"related-alts\">Dal\u0161\u00ed l\u00e9ky na sexu\u00e1ln\u00ed zdrav\u00ed<\/h2>\n<ul>\n<li><a href=\"\/cs\/tenvir-em\/\">Tenvir EM (TDF\/FTC 300+200 mg)<\/a><\/li>\n<li><a href=\"\/cs\/ricovir-em\/\">Ricovir EM (TDF\/FTC 300+200 mg)<\/a><\/li>\n<li><a href=\"\/cs\/tenof-em\/\">Tenof EM (TDF\/FTC 300+200 mg)<\/a><\/li>\n<li><a href=\"\/cs\/tavin-em\/\">Tavin EM (TDF\/FTC 300+200 mg)<\/a><\/li>\n<li><a href=\"\/cs\/std-protection-pack\/\">Bal\u00ed\u010dek ochrany proti STD<\/a><\/li>\n<\/ul>\n<p style=\"font-size:13px;color:#555;margin:14px 0;font-style:italic;\"><strong>Zdravotn\u00ed upozorn\u011bn\u00ed:<\/strong> Informace na t\u00e9to str\u00e1nce slou\u017e\u00ed pouze pro vzd\u011bl\u00e1vac\u00ed \u00fa\u010dely a nenahrazuj\u00ed l\u00e9ka\u0159skou pomoc. P\u0159ed zah\u00e1jen\u00edm, ukon\u010den\u00edm nebo zm\u011bnou jak\u00e9hokoli l\u00e9ku se v\u017edy pora\u010fte s kvalifikovan\u00fdm l\u00e9ka\u0159em.<\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 L\u00e9\u010dba HIV<br \/>\n\u2705 Sni\u017euje virovou n\u00e1lo\u017e<br \/>\n\u2705 Posiluje imunitn\u00ed syst\u00e9m<br \/>\n\u2705 Sni\u017euje riziko p\u0159enosu<br \/>\n\u2705 Zlep\u0161uje d\u00e9lku \u017eivota<\/p>\n<p>Taficita obsahuje Emtricitabine a Tenofovir.<\/p>","protected":false},"featured_media":61725,"comment_status":"closed","ping_status":"open","template":"","meta":[],"product_brand":[],"product_cat":[3141,3223,3304,3338],"product_tag":[5827,5819,3339,5674,5815,5816,5354,5825,5826,5083,4920],"class_list":{"0":"post-61724","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-category-overview","7":"product_cat-chronic-conditions","8":"product_cat-hiv-medication","9":"product_cat-prep-medication-pre-exposure-prophylaxis","10":"product_tag-descovy-generic","11":"product_tag-emcure-pharmaceuticals","12":"product_tag-emtricitabine","13":"product_tag-ftc","14":"product_tag-hiv-prevention","15":"product_tag-pre-exposure-prophylaxis","16":"product_tag-prep","17":"product_tag-taf","18":"product_tag-taf-ftc","19":"product_tag-taficita","20":"product_tag-tenofovir-alafenamide","22":"first","23":"instock","24":"shipping-taxable","25":"purchasable","26":"product-type-variable","27":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product\/61724","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/comments?post=61724"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/media\/61725"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/media?parent=61724"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_brand?post=61724"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_cat?post=61724"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_tag?post=61724"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}